|
Before fibrinolytic treatment | |
|
Do not administer rtPA if BP cannot be maintained ≤185/110 mm Hg | |
|
Patient eligible for rtPA administration except for SBP >185 mm Hg and/or DBP >110 mm Hg |
– IV labetalol 10-20 mg over 1-2 min, may be repeated once or – IV nicardipine 5 mg/h, titrate up by 2.5 mg/h every 5-15 min (max rate, 15 mg/h). When target BP is achieved, adjust to maintain appropriate BP range or – IV clevidipine 1-2 mg titrated by doubling the dose every 2-5 min until target is reached (max, 21 mg/h) or – Other agents (eg, hydralazine, enalaprilat) may be considered |
|
During or after fibrinolytic treatment | |
|
– Maintain BP ≤180/105 mm Hg (use IV labetalol 10 mg followed by infusion 2-8 mg/h, nicardipine (max, 15 mg/h), or clevidipine (max, 21 mg/h) – Monitor BP every 15 min for 2 h following the start of rtPA administration, then every 30 min for 6 h, and then every hour for 16 h | |
|
BP cannot be controlled with labetalol or nicardipine or DBP >140 mm Hg |
– Admission to ICU – IV sodium nitroprusside 0.5 microg/kg/min |
|
BP, blood pressure; DBP, diastolic blood pressure; ICU, intensive care unit; rtPA, recombinant tissue plasminogen activator; SBP, systolic blood pressure. | |